Management of Progressive Fibrosing Interstitial Lung Disease
For adults with progressive fibrosing ILD (excluding IPF), nintedanib should be initiated after failure of standard management, as it is the only antifibrotic agent with demonstrated efficacy in slowing lung function decline across multiple ILD subtypes. 1
Treatment Algorithm
First-Line Standard Management
Before considering antifibrotic therapy, implement disease-specific standard management:
- For CTD-ILD and inflammatory ILDs: Immunosuppressive therapy (typically mycophenolate mofetil) to attempt stabilization or reversal
- For hypersensitivity pneumonitis: Antigen identification and remediation
- For some patients: Observation may be appropriate if disease appears stable 1
Standard management varies by region and ILD subtype, as evidence-based guidance is lacking for many non-IPF ILDs 1.
Antifibrotic Therapy Selection
Nintedanib (Preferred)
- Conditional recommendation for PPF after failed standard management 1
- Demonstrated 107 ml/year reduction in FVC decline compared to placebo in the INBUILD trial (663 patients, 52 weeks) 1
- Efficacy varies by ILD subtype:
- CTD-ILD: 106.2 ml/year less decline
- Fibrotic NSIP: 141.7 ml/year less decline
- UIP pattern: 128 ml/year benefit
- Non-UIP pattern: 75.3 ml/year benefit 1
- Only antifibrotic approved for both SSc-ILD and PPF 2
Pirfenidone (Weaker Evidence)
- Conditional recommendation with significant committee abstention (38% abstained, citing insufficient evidence) 1
- Only 380 patients studied across trials, with 253 having poorly defined fibrotic ILD 1
- Evidence rated as very low quality due to early trial termination for futility and small sample sizes 1
Combination Therapy Considerations
Emerging practice patterns include combining antifibrotics with immunosuppression:
- Mycophenolate mofetil + nintedanib
- Biologics (rituximab, tocilizumab) + antifibrotics
- Caveat: Limited comparative data exists for combination approaches 2
Critical Adverse Effects to Monitor
Nintedanib causes substantial gastrointestinal toxicity:
- Diarrhea (2.8× increase)
- Nausea (3.1× increase)
- Vomiting (3.6× increase)
- Weight loss (3.7× increase)
- Elevated liver enzymes (AST 3.2×, ALT 3.6×)
- Dose reduction required 7.9 times more often than placebo
- Treatment discontinuation 1.9× higher 1
No significant increase in respiratory adverse effects, serious AEs, or severe AEs 1
Monitoring Requirements
Track disease progression through:
- Serial FVC measurements (primary outcome measure)
- High-resolution CT at diagnosis and during follow-up 2
- Six-minute walk test distance 3
- Symptom assessment (King's Brief ILD Questionnaire) 1
Approximately 20-30% of patients with SSc-ILD develop PPF, though reliable predictors remain elusive 2.
Common Pitfalls
- Delaying antifibrotic therapy: Once progression is documented despite standard management, initiate nintedanib promptly—FVC decline is continuous
- Using pirfenidone as first-line antifibrotic: The evidence base is substantially weaker than for nintedanib, with very low quality evidence and significant expert uncertainty 1
- Inadequate GI side effect counseling: Patients must be prepared for high rates of diarrhea and nausea to prevent premature discontinuation
- Missing early lung transplant referral: Advanced ILD can be rapidly fatal—refer early when progression is documented 3
Evidence Strength Considerations
The 2022 ATS/ERS/JRS/ALAT guidelines 1 provide the most authoritative recommendations. The nintedanib recommendation is based on the INBUILD trial (n=663), while pirfenidone evidence encompasses only 380 patients with heterogeneous definitions. The committee's 62% conditional support for pirfenidone versus 0% strong support, combined with 38% abstention, reflects genuine uncertainty about its role 1.
Recent expert perspectives 2 confirm nintedanib as the only approved antifibrotic for PPF, supporting its preferential use over pirfenidone in clinical practice.